Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_provenance.
- NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_assertion description "[While somatostatin receptors (sst), through somatostatin-radiolabeled analogs, are used, mainly in second line, in the diagnosis and treatment of pheochromocytomas (PCC) and paragangliomas (PGL), the clinical significance of dopamine receptor subtype 2 (D?) in PCC/PGL is unknown.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_provenance.
- NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_assertion evidence source_evidence_literature NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_provenance.
- NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_assertion SIO_000772 21335363 NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_provenance.
- NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_assertion wasDerivedFrom befree-2016 NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_provenance.
- NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_assertion wasGeneratedBy ECO_0000203 NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_provenance.
- befree-2016 importedOn "2016-02-19" NP873725.RAVObt4Gmx322DRZXZEcg26viOn6poHfaP_vtHccxaDbE130_provenance.